Navigation Links
Christopher Brennan Joins PharmaNet Development Group as General Counsel
Date:9/22/2009

PRINCETON, N.J., Sept. 22 /PRNewswire/ -- PharmaNet Development Group, Inc., a leading provider of clinical development services to innovative pharmaceutical, biotechnology, generic drug and medical device companies, announced today that Christopher S. Brennan has joined the Company as general counsel.

"We are very pleased to have Chris join the PharmaNet Development Group management team," commented Jeffrey P. McMullen, president and chief executive officer. "His diversified experience and expertise will bring valuable insight to the Company and support our growth strategies."

Previously, Mr. Brennan held the position of general counsel at a specialty pharmaceutical company and worked in private practice as a corporate transactional attorney at two prominent, multi-national law firms -- Cravath, Swaine & Moore LLP and Dechert LLP. While at these two global law firms, Mr. Brennan worked along side management teams from various Fortune 500 companies while helping them to successfully undertake and complete company "mission critical" transactions in the areas of mergers and acquisitions, corporate financing, joint ventures, licensing, corporate partnering, private financing and public securities -- all primarily in the pharmaceutical and emerging life science market place.

Mr. Brennan graduated from Fordham University School of Law with honors. For the five years prior to entering law school, he managed multi-million dollar, high-technology projects and led large project teams from various disciplines as a Captain in the United States Air Force.

About PharmaNet Development Group, Inc.

PharmaNet Development Group, Inc., a global drug development services company, provides a comprehensive range of services to the pharmaceutical, biotechnology, generic drug and medical device industries. The Company offers early and late stage consulting, Phase I clinical studies and bioanalytical analyses, and Phase II, III and IV clinical development programs. With approximately 2,300 employees and 40 facilities throughout the world, PharmaNet is a recognized leader in outsourced clinical development. For more information, please visit our website at www.pharmanet.com.

    Contact: Anne-Marie Hess
    Phone: (609) 951-6842
    E-mail: ahess@pharmanet.com


'/>"/>
SOURCE PharmaNet Development Group
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Clinsys Clinical Research, Inc. Announces Key Hires, Rajagopalan Srinivasan, Ph.D, to Strengthen Global Biostatistics Service Offering and Christopher Gregory, Ph.D, to Scientific Affairs
2. Christopher and Dana Reeve Foundation Awards Nearly $2 Million in Individual Research Grants
3. Quintiles Appoints Christopher Cabell to Chief Medical and Scientific Officer
4. Christopher Kurtz Joins Alexza Pharmaceuticals as Vice President, Global Supply Chain and Sustainment Engineering
5. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
6. Ameristar National Charity Golf Classic Raises More Than $1.1 Million for Buoniconti Fund to Cure Paralysis and Christopher & Dana Reeve Foundation
7. Christopher and Dana Reeve Foundation Response to FDA Clearance of Gerons Clinical Trial
8. VITAS Innovative Hospice Care(R) Names Christopher Rieder Senior Vice President and Chief Information Officer
9. Fina Technologies Names Spotfire Founder Christopher Ahlberg to Board of Directors
10. DeSilva + Phillips, Mediabankers, names Jim Brennan to Head Healthcare IT M&A Practice
11. Roche Joins Forces With Enon Tabernacle Baptist Church to Provide Free Hepatitis C Testing to the Community
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... , March 27, 2017 Cousins Properties (NYSE: ... world,s leading biotechnology companies, has signed a 10-year, approximately 125,000 ... A office asset located in the Westshore submarket of ... thrilled that Amgen has chosen Corporate Center for their new ... Gellerstedt , president and chief executive officer of Cousins Properties. ...
(Date:3/27/2017)... March 27, 2017 Infectex Ltd., a Russian portfolio company of ... study of SQ109 added to the standard drug therapy regimen in patients with multidrug-resistant ... Sequella, Inc. ( USA ) and the US National Institutes of Health. ... ... Biotech Venture Fund Logo ...
(Date:3/27/2017)... Va. , March 27, 2017  Perthera,s Chief ... Cancer Center, Subha Madhavan , Ph.D., will be ... Joint Summits Panels. On Monday, March 27, 2017, she ... Oncology Data More Usable for Research and Care" (from ... March 28, 2017, she will be a participant in ...
(Date:3/27/2017)... ... 2017 , ... PMG Research is pleased to announce its participation ... Conference Forum in Boston on April 3-4, 2017. The CTC conference focuses on how ... and bring them closer to the patient. Clinical Trial Collaborations also will present an ...
Breaking Biology Technology:
(Date:3/7/2017)... , March 7, 2017 Brandwatch , the ... by The Prince,s Trust to uncover insights to support ... The Trust. The UK,s leading youth charity will be ... campaign results and get a better understanding of the topics and ... ...
(Date:3/2/2017)... 2017 Who risk to be deprived of ... full report: https://www.reportbuyer.com/product/4313699/ WILL APPLE AND ... Fingerprint sensors using capacitive technology represent a fast ... Idex forecasts an increase of 360% of the number ... the fingerprint sensor market between 2014 and 2017 (source ...
(Date:2/28/2017)... , Spanien, 27. Februar 2017  EyeLock LLC, ein ... wird seine erstklassige biometrische Lösung zur Iris-Erkennung ... mit X16 LTE auf dem Mobile World ... am Qualcomm-Stand in Halle 3, Stand 3E10, ... die Sicherheitsplattform Qualcomm Haven™ – eine Kombination ...
Breaking Biology News(10 mins):